Michael Raymond Burgess MD PhD

Hematologic Oncology

Executive Director, Translational Medicine at Celgene

995 Potrero AveBldg 80San Francisco, CA 94110
Phone+1 415-206-2407
Fax+1 415-839-7018

Dr. Burgess is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Burgess' full profile Already have an account?

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2009 - 2013
University of California (San Francisco)Residency, Internal Medicine, 2007 - 2009
David Geffen School of Medicine at UCLAClass of 2007
University of California, Los AngelesPh.D., Molecular Biology, 2000 - 2005

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2008 - 2028
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers Start of enrollment: 2015 Mar 12
COMPLETED
PHASE1
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2016 Mar 01
TERMINATED
PHASE1
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma Start of enrollment: 2018 Apr 03
TERMINATED
PHASE1

Publications & Presentations

PubMed

11 citations
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class ...
Gayathri Ravi, Shambavi Richard, Shaji Kumar, Shebli Atrash, Michaela Liedtke
Leukemia. 2025-04-01
45 citations
Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.
Ningfei An, Saira Khan, Molly K. Imgruet, Sandeep Gurbuxani, Stephanie N. Konecki
Blood. 2018-06-14
89 citations
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
Nina Fenouille, Christopher F. Bassil, Issam Ben-Sahra, Lina Benajiba, Gabriela Alexe
Nature Medicine. 2017-03-01

Press Mentions

Danette Mitchell: The Road to a Cure for Sickle Cell DiseaseDecember 9th, 2021
Amazon Launches Health Centers to Boost Employee Access to CareJuly 15th, 2020
Whistleblower Dr. Rick Bright Warns 'Window Is Closing' to Address Coronavirus in Congressional TestimonyMay 14th, 2020